Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Revenue projections:

Revenue projections for ZTS
Revenue projections for ZTS

With ZTS's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 3.028000
forwardPE 15.073414
debtToEquity 279.586000
earningsGrowth 0.061000
revenueGrowth 0.030000
grossMargins 0.718920
operatingMargins 0.346880
trailingEps 6.020000
forwardEps 7.573600

ZTS's current ratio of 3.028, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as ZTS has enough cash and current assets to handle its immediate liabilities comfortably.
Zoetis Inc.'s Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
ZTS's elevated debt-to-equity ratio suggests the company is leveraging debt heavily, increasing its financial risk. While this can support growth, it could also lead to challenges if the company's profitability or cash flow weakens.
Zoetis Inc.'s positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.
With a forward EPS greater than its trailing EPS, Zoetis Inc. is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for ZTS
Price projections for ZTS

Zoetis Inc.'s price projections have gradually declined, indicating growing uncertainty about the company's ability to meet previous targets. The downward trend reflects a more conservative view of Zoetis Inc.'s future.

Insider Transactions:

Insider Transactions for ZTS
Insider Transactions for ZTS


4 Zoetis Inc. shares were sold in recent transactions, with market price at 158.01250076293945.During the period under review, no sell transactions were recorded.More buys than sells near the current price levels of ZTS might signal a favorable outlook for the stock. Investors seem to be showing confidence by purchasing more, potentially expecting positive future performance.

Recommendation changes over time:

Recommendations trend for ZTS
Recommendations trend for ZTS


Recent analysis shows a strong buy bias for Zoetis Inc., encouraging investors to view it as a solid investment option. The positive sentiment surrounding Zoetis Inc. suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.